VIMTALABS

Vimta Labs Share Price

₹771.20 +28.75 (3.87%)

21 Nov, 2024 14:45

SIP TrendupStart SIP in VIMTALABS

Start SIP

Performance

  • Low
  • ₹728
  • High
  • ₹776
  • 52 Week Low
  • ₹390
  • 52 Week High
  • ₹804
  • Open Price₹744
  • Previous Close₹742
  • Volume87,937

Investment Returns

  • Over 1 Month + 36.48%
  • Over 3 Month + 53.85%
  • Over 6 Month + 53.31%
  • Over 1 Year + 82.76%
SIP Lightning

Smart Investing Starts Here Start SIP with Vimta Labs for Steady Growth!

Invest Now

Vimta Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.3
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 1,713
  • P/B Ratio
  • 5.4
  • Average True Range
  • 42.04
  • EPS
  • 24.04
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 34.07
  • RSI
  • 69.43
  • MFI
  • 85.41

Vimta Labs Financials

Vimta Labs Technicals

EMA & SMA

Current Price
₹771.20
+ 28.75 (3.87%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹654.71
  • 50 Day
  • ₹604.28
  • 100 Day
  • ₹572.01
  • 200 Day
  • ₹536.83

Resistance and Support

751.17 Pivot Speed
  • R3 865.23
  • R2 830.12
  • R1 786.28
  • S1 707.33
  • S2 672.22
  • S3 628.38

What's your outlook on Vimta Labs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vimta Labs Ltd. offers a wide range of testing, inspection, and analytical services, specializing in pharmaceuticals, food, and environmental testing. Serving clients globally, it provides high-quality, accredited lab services to ensure product safety and regulatory compliance.

Vimta Labs has an operating revenue of Rs. 327.86 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 17% is great, ROE of 12% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 25% and 41% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 6% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 31 indicates it belongs to a strong industry group of Medical-Services and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vimta Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-08 Quarterly Results
2024-07-17 Quarterly Results
2024-05-18 Audited Results & Final Dividend
2024-03-30 Amalgamation
2024-01-31 Quarterly Results
Date Purpose Remarks
2022-06-18 FINAL Rs.2.00 per share(100%)Dividend
2021-06-28 FINAL Rs.2.00 per share(100%)Dividend

Vimta Labs F&O

Vimta Labs Shareholding Pattern

36.89%
0%
3.31%
0%
26.53%
33.27%

About Vimta Labs

  • NSE Symbol
  • VIMTALABS
  • BSE Symbol
  • 524394
  • Managing Director
  • Ms. Harita Vasireddi
  • ISIN
  • INE579C01029

Similar Stocks to Vimta Labs

Vimta Labs FAQs

Vimta Labs share price is ₹771 As on 21 November, 2024 | 14:31

The Market Cap of Vimta Labs is ₹1713.1 Cr As on 21 November, 2024 | 14:31

The P/E ratio of Vimta Labs is 34.3 As on 21 November, 2024 | 14:31

The PB ratio of Vimta Labs is 5.4 As on 21 November, 2024 | 14:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23